FDA Advisory Panel Approves GlaxoSmithKline Diabetes Drug

July 31, 2007 - GlaxoSmithKline announced the recommendation of an FDA advisory committee to support Avandia’s (rosiglitazone maleate), an oral anti-diabetic medicine, continued availability to patients in the U.S., information which the FDA will consider its final decision-making process.
On July 30th, the FDA Endocrinologic and Metabolic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee voted that the data suggests some ischemic risk with Avandia, a treatment for type 2 diabetes, yet the committee voted to keep the medicine available to patients in the U.S. The FDA will review the panel's recommendation before making a decision.